Skip to main content
MyPeptideMatch logoMyPeptideMatch
Reviewed by MyPeptideMatch Editorial TeamLast reviewed February 2026Updated February 2026

SLU-PP-332 Dosing Protocol: 10 mg Vial — ERR Agonist & Cardio Mimetic Guide

SLU-PP-332 ERRalpha/gamma agonist dosing guide — exercise mimetic for cardiac mitochondrial biogenesis and endurance optimization.

Go to peptide profileCalculate your dose

Quickstart highlights

SLU-PP-332 is a synthetic ERR (estrogen-related receptor) alpha/gamma agonist developed at Washington University School of Medicine.

  • Concentration: 2 mg/mL (10 mg vial + 5 mL bacteriostatic water).
  • At 2 mg/mL: 3 mg = 150 units per morning injection.
  • Tripathi et al. 2024: SLU-PP-332 improved cardiac function and mitochondrial biogenesis in HF mouse models.
  • ERRalpha/gamma agonism drives PGC-1alpha and oxidative metabolism genes — the same program as endurance training.
  • No human clinical trials exist as of 2026; all evidence is preclinical.

Dosing table

For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.

WeekDose (µg)UnitsFrequencyNotes
1-2—50Once daily (morning)1 mg — 50 units; starting dose; assess energy and thermogenic response
3-8—150Once daily (morning)3 mg — 150 units; intermediate dose used in Tripathi et al. 2024 rat studies at scaled equivalent
alt—250Once daily (morning)5 mg — 250 units; exploratory maximum; one 10 mg vial provides 2 doses at this level

Reconstitution steps

  1. Draw 5 mL bacteriostatic water (two 2.5 mL draws); inject slowly down the vial wall.
  2. Swirl gently until dissolved; do not shake.
  3. Final concentration: 2 mg/mL. At 2 mg/mL: 1 mg = 50 units, 3 mg = 150 units, 5 mg = 250 units.
  4. Label with date; refrigerate at 2–8 °C. Use within 28 days.

Supplies needed

8-week plan

  • 5 vials
  • 56 syringes
  • 25 mL bac water
  • 56 alcohol swabs
Need clinics? See vetted providers →

Protocol overview & cycle notes

Activate ERRalpha and ERRgamma nuclear receptors to drive cardiac and skeletal muscle mitochondrial biogenesis, PGC-1alpha expression, and oxidative metabolism programs that mirror endurance training adaptations.

Cycle length: 8 weeks on.

Off-cycle: 4 weeks off after each 8-week cycle; assess cardiovascular fitness markers before resuming.

Storage & handling

Lyophilized: store at -20 °C for maximum stability. Reconstituted at 2 mg/mL: refrigerate 2–8 °C; use within 14 days (SLU-PP-332 has limited aqueous stability data — conservative window recommended). Protect from light.

Injection & tracking tips

  • Inject subcutaneously in the morning, 30–60 minutes before aerobic exercise for maximum synergistic effect on PGC-1alpha and cardiac mitochondrial biogenesis.
  • SLU-PP-332 acts via ERRalpha/gamma receptors — unlike AICAR (AMPK), it does not require cellular energy depletion to activate and may be more suitable for non-fasted administration.
  • Cardiac ERR signaling is particularly sensitive: some users report increased exercise tolerance and lower resting heart rate within 2–4 weeks.

Tracking

Logging helps you and your provider spot patterns and adjust dose or timing.

  • Measure VO2max (submaximal cycling or treadmill test) at baseline and every 4 weeks.
  • Track resting heart rate as a cardiac efficiency indicator weekly.
  • Record subjective exercise tolerance and time to fatigue during standard cardio workouts.
Log your cycle in the calculator →

How this works & references

SLU-PP-332 is a synthetic ERR (estrogen-related receptor) alpha/gamma agonist developed at Washington University School of Medicine. ERRalpha and ERRgamma are orphan nuclear receptors that govern oxidative metabolism gene expression in the heart, skeletal muscle, and adipose tissue. Unlike ERalpha (estrogen receptor), they do not bind estrogens. SLU-PP-332 binds the ERR ligand-binding domain with nanomolar affinity, driving transcription of PGC-1alpha, cytochrome c oxidase subunits, and fatty acid beta-oxidation genes — the same gene set induced by endurance exercise. Tripathi et al. (2024, Nature Communications) demonstrated that SLU-PP-332 significantly improved cardiac function, reduced cardiac hypertrophy, and enhanced mitochondrial biogenesis in heart failure mouse models.

Sources

  • Source: Tripathi S et al. — ERRgamma agonist SLU-PP-332 improves cardiac function in heart failure models. Nat Commun. 2024
  • Source: Kim DH et al. — ERR agonists promote oxidative metabolism and exercise capacity. Nat Chem Biol. 2023

Frequently asked questions

How is SLU-PP-332 different from AICAR?
Both are exercise mimetics but via distinct pathways: AICAR activates AMPK (energy-sensing kinase), primarily enhancing glucose uptake, fat oxidation, and mitochondrial biogenesis in skeletal muscle. SLU-PP-332 activates ERRalpha/gamma nuclear receptors, directly driving transcription of mitochondrial biogenesis genes in cardiac and skeletal muscle — particularly strong cardiac effects. SLU-PP-332 does not require cellular AMP elevation and may be more cardiac-specific.
What is ERRalpha/gamma and why does activating it enhance endurance?
ERRalpha (ESRRA) and ERRgamma (ESRRG) are orphan nuclear receptors that control oxidative phosphorylation gene expression — essentially the on/off switch for the aerobic metabolism phenotype. High ERR activity = high mitochondrial density = high oxidative capacity = endurance phenotype. Exercise training increases ERR activity; SLU-PP-332 activates ERR directly without requiring exercise.
Can SLU-PP-332 cause cardiac arrhythmias?
ERRgamma is highly expressed in cardiac conduction tissue and regulates ion channel expression. Pharmacological ERR agonism at high doses theoretically could affect cardiac rhythm. Tripathi et al. (2024) reported no arrhythmias in mouse models at therapeutic doses. Given the absence of human safety data, SLU-PP-332 is contraindicated in individuals with known arrhythmia, long QT syndrome, or significant structural heart disease.
Is SLU-PP-332 on the WADA prohibited list?
As of 2026, SLU-PP-332 is not specifically listed on the WADA prohibited substance list. However, WADA prohibits any substance from the category of metabolic modulators (S4.4) that could enhance athletic performance. WADA may add SLU-PP-332 as awareness grows. Athletes should consult their national anti-doping organization for current classification.
How many 10 mg vials do I need for an 8-week protocol at 3 mg/day?
3 mg/day x 56 days = 168 mg total. At 10 mg per vial and 5 doses per vial (at 2 mg/mL, 5 mL total reconstitution, 3 mg = 1.5 mL per dose): 168 mg ÷ 10 mg per vial = approximately 17 vials for the full 8 weeks. For a more economical approach, cycling 5 days on / 2 days off reduces total consumption to 120 mg = 12 vials.

Related protocols

Vilon Dosing Protocol: 20 mg Vial — Dipeptide Immune & Longevity Bioregulator Guide

Vilon (Lys-Glu dipeptide) Russian immune and longevity bioregulator dosing guide — the simplest Khavinson bioregulator for systemic immune normalization and longevity support.

View protocol

Vesugen Dosing Protocol: 20 mg Vial — Vascular Bioregulator & Cardiovascular Guide

Vesugen (Lys-Glu-Asp tetrapeptide) Russian vascular bioregulator dosing guide — endothelial cell gene normalization for arterial health, blood pressure regulation, and cardiovascular aging.

View protocol

Testagen Dosing Protocol: 20 mg Vial — Testicular Bioregulator & Testosterone Support Guide

Testagen (Lys-Glu-Asp-Gly tetrapeptide) Russian testicular bioregulator dosing guide — Leydig cell gene normalization for testosterone production optimization and male reproductive aging support.

View protocol

Prostamax Dosing Protocol: 20 mg Vial — Prostate Bioregulator Guide

Prostamax (Lys-Asp-Glu-Leu tetrapeptide) Russian prostate bioregulator dosing guide — prostatic epithelial gene normalization for BPH, prostate aging, and urinary symptom support.

View protocol

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.

Need help?

Browse vetted clinicsView full peptide profile →